RxDoctor Payments DataLook up a doctor →

Arjun Haridas

Endocrinology, Diabetes & Metabolism · Roswell, GANPI 1497146062

Payments from drug & device makers

$13,374in general payments, 2019–2025

Across 718 payments — averaging $18.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • Sanofi-aventis U.S. LLC$973
  • Amgen$737
  • Corcept Therapeutics$698
  • AstraZeneca$597
  • plus $7K from 47 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk122$1,759
Lilly USA, LLC87$1,476
Sanofi-aventis U.S. LLC36$973
Amgen(2 entities)34$737
Corcept Therapeutics36$698
AstraZeneca(2 entities)25$597
Xeris Pharmaceuticals, Inc.31$546
IBSA Pharma Inc.31$535
Tandem Diabetes Care, Inc.26$516
Amneal Pharmaceuticals LLC26$427
Mannkind Corporation12$381
AbbVie20$379
Antares Pharma, Inc.22$378
Abbott21$337
Boehringer Ingelheim19$330
Esperion Therapeutics, Inc.13$321
Bayer17$314
Novartis13$245
Zealand Pharma US, Inc.11$222
Dexcom, Inc.13$216
Insulet Corporation9$209
BETA Bionics, Inc.4$183
Ascensia Diabetes Care US Inc.9$179
Radius Health, Inc.7$172
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC9$162
Amarin Pharma, Inc.10$138
Cequr Corporation6$106
Merck6$82
Medtronic(2 entities)4$74
Sequel Med Tech, LLC3$67
Ipsen Biopharmaceuticals, Inc3$57
Pfizer3$52
Vivus LLC3$50
Halozyme Inc2$40
Currax Pharmaceuticals LLC3$39
Exact Sciences2$35
Nestle Healthcare Nutrition Inc.2$32
Ascendis Pharma Endocrinology Inc2$29
Madrigal Pharmaceuticals1$27
Recordati_rare_diseases_inc.2$26
Shire North American Group Inc1$24
Astellas Pharma US Inc1$23
Ultragenyx Pharmaceutical Inc.1$20
Kyowa Kirin, Inc.1$19
Amphastar Pharmaceuticals, Inc.1$18
Bigfoot Biomedical Inc1$18
Verity Pharmaceuticals Inc.1$17
Acella Pharmaceuticals, LLC1$17
Kowa Pharmaceuticals America, Inc.1$15
Azurity Pharmaceuticals, Inc.1$15
Neurocrine Biosciences, Inc.1$14
Amryt Pharma Holdings Ltd1$14
GRT US Holding, Inc.1$13

How this compares

$13,374 in reported general payments places this provider in the 80th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

See all endocrinology, diabetes & metabolism providers in Georgia →

Medicare billing

Part B allowed, 2024
$18,354
Medicare patients
68
Services billed
172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Roswell

See the full list for Georgia →

Where these figures come from

Is this you, or does something look wrong? →